Skip to main content
SpringerLink
Log in

Immune Dysfunction and Immunosuppression: Impacts on SCC Incidence, Prognosis, and Management

  • Chapter
  • First Online:
High-Risk Cutaneous Squamous Cell Carcinoma

  • 625 Accesses

Abstract

Immune function plays a major role in the development of cutaneous squamous cell carcinoma (SCC). Locally within the skin, ultraviolet damage creates immune dysfunction which serves as a nidus for many keratinocytic malignancies. Furthermore, patients with systemic immune dysfunction or dysregulation are subject to forming multiple SCCs and have a higher risk of developing biologically aggressive tumors. Proper balancing and targeting of immune function to treat disease while avoiding malignancy continues to inspire research. Immune modulation is an emerging area of cancer therapeutics, a mainstay of treatment of immunosuppressive disease, and is vital in the prevention of organ rejection in solid organ transplant patients. The central role of the immune system in the etiology and outcomes of SCC inspired the editors of this book to include a practical approach to management of patients with immunologic alteration, whether iatrogenic or disease-induced, as proper management can be quite complex. The initial portion of this chapter will set the background for immune dysfunction both locally and systemically for the development of SCC. The latter portion will focus on strategies for prevention, treatment, and management of SCC patients with immune dysfunction, with a particular focus on transplant patients and other immunosuppressed states.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Schwarz T. The dark and the sunny sides of UVR-induced immunosuppression: photoimmunology revisited. J Invest Dermatol. 2010;130(1):49–54.

    Article  CAS  PubMed  Google Scholar 

  2. Czesnikiewicz-Guzik M, Lee WW, Cui D, et al. T cell subset-specific susceptibility to aging. Clin Immunol. 2008;127(1):107–18.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Boehnke K, Falkowska-Hansen B, Stark HJ, Boukamp P. Stem cells of the human epidermis and their niche: composition and function in epidermal regeneration and carcinogenesis. Carcinogenesis. 2012;33(7):1247–58.

    Article  CAS  PubMed  Google Scholar 

  4. White AC, Tran K, Khuu J, et al. Defining the origins of Ras/p53-mediated squamous cell carcinoma. Proc Natl Acad Sci U S A. 2011;108(18):7425–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Meyer KC, Klatte JE, Dinh HV, et al. Evidence that the bulge region is a site of relative immune privilege in human hair follicles. Br J Dermatol. 2008;159(5):1077–85.

    CAS  PubMed  Google Scholar 

  6. Chen CJ, Sung WW, Su TC, et al. High expression of interleukin 10 might predict poor prognosis in early stage oral squamous cell carcinoma patients. Clin Chim Acta. 2013;415:25–30.

    Article  CAS  PubMed  Google Scholar 

  7. Pandey S, Mercer SE, Dallas K, Emanuel PO, Goldenberg G. Evaluation of the prognostic significance of follicular extension in actinic keratoses. J Clin Aesthet Dermatol. 2012;5(4):25–8.

    PubMed  PubMed Central  Google Scholar 

  8. Plikus MV, Gay DL, Treffeisen E, Wang A, Supapannachart RJ, Cotsarelis G. Epithelial stem cells and implications for wound repair. Semin Cell Dev Biol. 2012;23(9):946–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Nguyen TH, Yoon J. Squamous cell carcinoma. In: Rigel D, Firedman RJ, Dzubow LM, Reintgen DS, Bystryn JC, Marks R, editors. Cancer of the skin. New York: Elsevier; 2005. p. 133–50.

    Google Scholar 

  10. Weber F, Bauer JW, Sepp N, et al. Squamous cell carcinoma in junctional and dystrophic epidermolysis bullosa. Acta Derm Venereol. 2001;81:189–92.

    Article  CAS  PubMed  Google Scholar 

  11. Goedert JJ, Cote TR, Virgo P, et al. Spectrum of AIDS-associated malignant disorders. Lancet. 1998;351(9119):1833–9.

    Article  CAS  PubMed  Google Scholar 

  12. Franceschi S, Dal Maso L, Arniani S, et al. Risk of cancer other than Kaposi’s sarcoma and non-Hodgkin’s lymphoma in persons with AIDS in Italy. Cancer and AIDS registry linkage study. Br J Cancer. 1998;78(7):966–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Garlassi E, Harding V, Weir J, et al. Nonmelanoma skin cancers among HIV-infected persons in the HAART era. J Acquir Immune Defic Syndr. 2012;60(2):e63–5.

    Article  PubMed  Google Scholar 

  14. Silverberg MJ, Leyden W, Warton EM, Quesenberry Jr CP, Engels EA, Asgari MM. HIV infection status, immunodeficiency, and the incidence of non-melanoma skin cancer. J Natl Cancer Inst. 2013;105(5):350–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Nguyen P, Vin-Christian K, Ming ME, Berger T. Aggressive squamous cell carcinomas in persons infected with the human immunodeficiency virus. Arch Dermatol. 2002;138(6):758–63.

    Article  PubMed  Google Scholar 

  16. Hausauer AK, Maurer T, Leslie KS, Parvataneni R, Stuart SE, Chren MM. Recurrence after treatment of cutaneous basal cell and squamous cell carcinomas in patients infected with human immunodeficiency virus. JAMA Dermatol. 2013;149(2):239–41.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst. 2000;92(18):1500–10.

    Article  CAS  PubMed  Google Scholar 

  18. Durante AJ, Williams AB, Da Costa M, Darragh TM, Khoshnood K, Palefsky JM. Incidence of anal cytological abnormalities in a cohort of human immunodeficiency virus-infected women. Cancer Epidemiol Biomarkers Prev. 2003;12(7):638–42.

    PubMed  Google Scholar 

  19. Palefsky JM, Holly EA, Ralston ML, Jay N, Berry JM, Darragh TM. High incidence of anal high-grade squamous intra-epithelial lesions among HIV-positive and HIV-negative homosexual and bisexual men. AIDS. 1998;12(5):495–503.

    Article  CAS  PubMed  Google Scholar 

  20. Wilkins K, Dolev JC, Turner R, LeBoit PE, Berger TG, Maurer TA. Approach to the treatment of cutaneous malignancy in HIV-infected patients. Dermatol Ther. 2005;18(1):77–86.

    Article  PubMed  Google Scholar 

  21. Mehrany K, Weenig RH, Pittelkow MR, Roenigk RK, Otley CC. High recurrence rates of squamous cell carcinoma after Mohs’ surgery in patients with chronic lymphocytic leukemia. Dermatol Surg. 2005;31(1):38–42.

    Article  CAS  PubMed  Google Scholar 

  22. Mehrany K, Weenig RH, Lee KK, Pittelkow MR, Otley CC. Increased metastasis and mortality from cutaneous squamous cell carcinoma in patients with chronic lymphocytic leukemia. J Am Acad Dermatol. 2005;53(6):1067–71.

    Article  PubMed  Google Scholar 

  23. Mehrany K, Byrd DR, Roenigk RK, et al. Lymphocytic infiltrates and subclinical epithelial tumor extension in patients with chronic leukemia and solid-organ transplantation. Dermatol Surg. 2003;29(2):129–34.

    PubMed  Google Scholar 

  24. Toro JR, Blake PW, Bjorkholm M, Kristinsson SY, Wang Z, Landgren O. Prior history of non-melanoma skin cancer is associated with increased mortality in patients with chronic lymphocytic leukemia. Haematologica. 2009;94(10):1460–4.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Velez NF, Karia PS, Vartanov AR, Davids MS, Brown JR, Neel VA, Davids MS, Schmults CD. Association of advanced leukemic stage and skin cancer tumor stage with poor skin cancer outcomes in patients with chronic lymphocytic leukemia. JAMA Dermatol. 2014;150(3):280–7.

    Article  PubMed  Google Scholar 

  26. Urbanska M, Nowak G, Florek E. Cigarette smoking and its influence on skin aging. Przegl Lek. 2012;69(10):1111–4.

    PubMed  Google Scholar 

  27. Thompson SC, Jolley D, Marks R. Reduction of solar keratoses by regular sunscreen use. N Engl J Med. 1993;329(16):1147–51.

    Article  CAS  PubMed  Google Scholar 

  28. Ulrich C, Jurgensen JS, Degen A, et al. Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case–control study. Br J Dermatol. 2009;161 Suppl 3:78–84.

    Article  PubMed  Google Scholar 

  29. Mofenson LM, Brady MT, Danner SP, et al. Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the pediatric Infectious Diseases Society, and the American Academy of Pediatrics. MMWR Recomm Rep. 2009;58(RR-11):1–166.

    PubMed  PubMed Central  Google Scholar 

  30. Christenson LJ, Cherikh WS, Otley CC, Salasche SJ, Kauffman HM. Allograft and overall survival of patients with posttransplant skin cancer. Dermatol Surg. 2011;37(2):183–91.

    Article  CAS  PubMed  Google Scholar 

  31. Ritchie SA, Patel MJ, Miller SJ. Therapeutic options to decrease actinic keratosis and squamous cell carcinoma incidence and progression in solid organ transplant recipients: a practical approach. Dermatol Surg. 2012;38(10):1604–21.

    Article  CAS  PubMed  Google Scholar 

  32. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med. 2003;348(17):1681–91.

    Article  PubMed  Google Scholar 

  33. Stasko T, Brown MD, Carucci JA, et al. Guidelines for the management of squamous cell carcinoma in organ transplant recipients. Dermatol Surg. 2004;30(4 Pt 2):642–50.

    PubMed  Google Scholar 

  34. Jensen P, Moller B, Hansen S. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol. 2000;42(2 Pt 1):307.

    Article  CAS  PubMed  Google Scholar 

  35. Wisgerhof HC, Wolterbeek R, de Fijter JW, Willemze R, Bouwes Bavinck JN. Kidney transplant recipients with cutaneous squamous cell carcinoma have an increased risk of internal malignancy. J Invest Dermatol. 2012;132(9):2176–83.

    Article  CAS  PubMed  Google Scholar 

  36. Thomas BR, Barnabas A, Agarwal K, et al. Patient perception of skin-cancer prevention and risk after liver transplantation. Clin Exp Dermatol. 2013;38(8):851–6.

    Article  CAS  PubMed  Google Scholar 

  37. Alessi SS, Sanches JA, Oliveira WR, Messina MC, Pimentel ER, Festa Neto C. Treatment of cutaneous tumors with topical 5% imiquimod cream. Clinics (Sao Paulo). 2009;64(10):961–6.

    Article  Google Scholar 

  38. Cusini M, Salmaso F, Zerboni R, et al. 5% imiquimod cream for external anogenital warts in HIV-infected patients under HAART therapy. Int J STD AIDS. 2004;15(1):17–20.

    Article  CAS  PubMed  Google Scholar 

  39. Richel O, de Vries HJ, van Noesel CJ, Dijkgraaf MG, Prins JM. Comparison of imiquimod, topical fluorouracil, and electrocautery for the treatment of anal intraepithelial neoplasia in HIV-positive men who have sex with men: an open-label, randomised controlled trial. Lancet Oncol. 2013;14(4):346–53.

    Article  CAS  PubMed  Google Scholar 

  40. Zwald FO, Brown M. Skin cancer in solid organ transplant recipients: advances in therapy and management: part II. management of skin cancer in solid organ transplant recipients. J Am Acad Dermatol. 2011;65(2):263–79.

    Article  PubMed  Google Scholar 

  41. Ulrich C, Bichel J, Euvrard S, et al. Topical immunomodulation under systemic immunosuppression: results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients. Br J Dermatol. 2007;157 Suppl 2:25–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Saiag P, Bauhofer A, Bouscarat F, et al. Imiquimod 5% cream for external genital or perianal warts in human immunodeficiency virus-positive patients treated with highly active antiretroviral therapy: an open-label, noncomparative study. Br J Dermatol. 2009;161(4):904–9.

    Article  CAS  PubMed  Google Scholar 

  43. De Socio GV, Simonetti S, Rosignoli D, Minga P, Tomassini GM, Baldelli F. Topical cidofovir for severe warts in a patient affected by AIDS and Hodgkin’s lymphoma. Int J STD AIDS. 2008;19(10):715–6.

    Article  PubMed  Google Scholar 

  44. Kralund HH, Broesby-Olsen S, Bistrup C, Lorentzen HF. Substantial effect of topical cidofovir 1% on recalcitrant warts in a renal-transplanted adolescent: a case report. Transplantation. 2011;91(7):e52–4.

    Article  PubMed  Google Scholar 

  45. Juschka U, Hartmann M. Topical treatment of common warts in an HIV-positive patient with imiquimod 5% cream. Clin Exp Dermatol. 2003;28 Suppl 1:48–50.

    Article  PubMed  Google Scholar 

  46. Summers P, Richards-Altmon P, Halder R. Treatment of recalcitrant verruca vulgaris with Candida antigen in patient with human immunodeficiency virus. J Drugs Dermatol. 2009;8(3):268–9.

    PubMed  Google Scholar 

  47. Shah M, Murphy M, Price JD, Lacey CJ. Intralesional bleomycin for the treatment of non-genital warts in HIV-infected patients. Acta Derm Venereol. 1996;76(1):81–2.

    CAS  PubMed  Google Scholar 

  48. Kovach BT, Sams HH, Stasko T. Systemic strategies for chemoprevention of skin cancers in transplant recipients. Clin Transplant. 2005;19(6):726–34.

    Article  PubMed  Google Scholar 

  49. Kovach BT, Stasko T. Skin cancer after transplantation. Transplant Rev (Orlando). 2009;23(3):178–89.

    Article  Google Scholar 

  50. Rook AH, Jaworsky C, Nguyen T, et al. Beneficial effect of low-dose systemic retinoid in combination with topical tretinoin for the treatment and prophylaxis of premalignant and malignant skin lesions in renal transplant recipients. Transplantation. 1995;59(5):714–9.

    Article  CAS  PubMed  Google Scholar 

  51. George R, Weightman W, Russ GR, Bannister KM, Mathew TH. Acitretin for chemoprevention of non-melanoma skin cancers in renal transplant recipients. Australas J Dermatol. 2002;43(4):269–73.

    Article  PubMed  Google Scholar 

  52. Otley CC, Stasko T, Tope WD, Lebwohl M. Chemoprevention of nonmelanoma skin cancer with systemic retinoids: practical dosing and management of adverse effects. Dermatol Surg. 2006;32(4):562–8.

    CAS  PubMed  Google Scholar 

  53. Bruno S, Ghiotto F, Tenca C, et al. N-(4-hydroxyphenyl)retinamide promotes apoptosis of resting and proliferating B-cell chronic lymphocytic leukemia cells and potentiates fludarabine and ABT-737 cytotoxicity. Leukemia. 2012;26(10):2260–8.

    Article  CAS  PubMed  Google Scholar 

  54. Saeed AT, Murphy P, Napoletano S. Role of synthetic retinoic acid derivatives in chronic lymphocytic leukemia and multiple myeloma. BMC Proc. 2013;7 Suppl 1:O3.

    PubMed Central  Google Scholar 

  55. Hasson A, Navarrete-Dechent C, Nicklas C, de la Cruz C. Topical photodynamic therapy with methylaminolevulinate for the treatment of actinic keratosis and reduction of photodamage in organ transplant recipients: a case-series of 16 patients. Indian J Dermatol Venereol Leprol. 2012;78(4):448–53.

    Article  PubMed  Google Scholar 

  56. Willey A, Mehta S, Lee P. Reduction in the incidence of squamous cell carcinoma in solid organ transplant recipients treated with cyclic photodynamic therapy. Dermatol Surg. 2010;36(5):652–8.

    Article  CAS  PubMed  Google Scholar 

  57. Perrett CM, McGregor JM, Warwick J, et al. Treatment of post-transplant premalignant skin disease: a randomized intrapatient comparative study of 5-fluorouracil cream and topical photodynamic therapy. Br J Dermatol. 2007;156(2):320–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Helsing P, Togsverd-Bo K, Veierod MB, Mork G, Haedersdal M. Intensified fractional CO laser-assisted photodynamic therapy versus laser alone for organ transplant recipients with multiple actinic keratoses and wart-like lesions: a randomized half-side comparative trial on dorsal hands. Br J Dermatol. 2013.

    Google Scholar 

  59. Otley CC. Organization of a specialty clinic to optimize the care of organ transplant recipients at risk for skin cancer. Dermatol Surg. 2000;26(7):709–12.

    Article  CAS  PubMed  Google Scholar 

  60. Connolly SM, Baker DR, Coldiron BM, et al. AAD/ACMS/ASDSA/ASMS 2012 appropriate use criteria for Mohs micrographic surgery: a report of the American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery. Dermatol Surg. 2012;38:1582–603.

    Article  CAS  PubMed  Google Scholar 

  61. National Comprehensive Cancer Network. Basal cell and squamous cell skin cancers. NCCN clinical practice guidelines in oncology, version 1. 2013. http://www.nccn.org/professionals/physician_gls/PDF/nmsc.pdf. Accessed 01 May 2013.

  62. Ad Hoc Task Force, Connolly SM, Baker DR, Coldiron BM, Fazio MJ, Storrs PA, Vidimos AT, et al. AAD/ACMS/ASDSA/ASMS 2012 appropriate use criteria for Mohs micrographic surgery: a report of the American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery. J Am Acad Dermatol. 2012;67:531–50.

    Article  Google Scholar 

  63. de Graaf YG, Basdew VR, van Zwan-Kralt N, Willemze R, Bavinck JN. The occurrence of residual or recurrent squamous cell carcinomas in organ transplant recipients after curettage and electrodesiccation. Br J Dermatol. 2006;154(3):493–7.

    Article  PubMed  Google Scholar 

  64. Smoller BR, Warnke RA. Cutaneous infiltrate of chronic lymphocytic leukemia and relationship to primary cutaneous epithelial neoplasms. J Cutan Pathol. 1998;25(3):160–4.

    Article  CAS  PubMed  Google Scholar 

  65. Kaplan AL, Cook JL. Cutaneous squamous cell carcinoma in patients with chronic lymphocytic leukemia. Skinmed. 2005;4(5):300–4.

    Article  PubMed  Google Scholar 

  66. Bellman BA, Eaglstein WH, Miller J. Low dose isotretinoin in the prophylaxis of skin cancer in renal transplant patients. Transplantation. 1996;61(1):173.

    Article  CAS  PubMed  Google Scholar 

  67. Shuttleworth D, Marks R, Griffin PJ, Salaman JR. Treatment of cutaneous neoplasia with etretinate in renal transplant recipients. Q J Med. 1988;68(257):717–25.

    CAS  PubMed  Google Scholar 

  68. Endrizzi B, Ahmed RL, Ray T, Dudek A, Lee P. Capecitabine to reduce nonmelanoma skin carcinoma burden in solid organ transplant recipients. Dermatol Surg. 2013;39(4):634–45.

    Article  CAS  PubMed  Google Scholar 

  69. O’Bryan K, Sherman W, Niedt GW, et al. An evolving paradigm for the workup and management of high-risk cutaneous squamous cell carcinoma. J Am Acad Dermatol. 2013;69(4):595–602.e1.

    Article  PubMed  Google Scholar 

  70. Leard LE, Cho BK, Jones KD, et al. Fatal diffuse alveolar damage in two lung transplant patients treated with cetuximab. J Heart Lung Transplant. 2007;26(12):1340–4.

    Article  PubMed  Google Scholar 

  71. Pennington BE, Stasko T. NMSC in organ transplant recipients and other high-risk groups. J Natl Compr Canc Netw. 2004;2(1):31–41.

    PubMed  Google Scholar 

  72. Leblanc Jr KG, Hughes MP, Sheehan DJ. The role of sirolimus in the prevention of cutaneous squamous cell carcinoma in organ transplant recipients. Dermatol Surg. 2011;37(6):744–9.

    CAS  PubMed  Google Scholar 

  73. Kuhn DJ, Dou QP. Direct inhibition of interleukin-2 receptor alpha-mediated signaling pathway induces G1 arrest and apoptosis in human head-and-neck cancer cells. J Cell Biochem. 2005;95(2):379–90.

    Article  CAS  PubMed  Google Scholar 

  74. Dantal J, Hourmant M, Cantarovich D, et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet. 1998;351(9103):623–8.

    Article  CAS  PubMed  Google Scholar 

  75. Otley CC, Coldiron BM, Stasko T, Goldman GD. Decreased skin cancer after cessation of therapy with transplant-associated immunosuppressants. Arch Dermatol. 2001;137(4):459–63.

    CAS  PubMed  Google Scholar 

  76. Moloney FJ, Kelly PO, Kay EW, Conlon P, Murphy GM. Maintenance versus reduction of immunosuppression in renal transplant recipients with aggressive squamous cell carcinoma. Dermatol Surg. 2004;30(4 Pt 2):674–8.

    CAS  PubMed  Google Scholar 

  77. Hoogendijk-van den Akker JM, Harden PN, Hoitsma AJ, et al. Two-year randomized controlled prospective trial converting treatment of stable renal transplant recipients with cutaneous invasive squamous cell carcinomas to sirolimus. J Clin Oncol. 2013;31(10):1317–23.

    Article  CAS  PubMed  Google Scholar 

  78. Euvrard S, Morelon E, Rostaing L, et al. Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med. 2012;367(4):329–39.

    Article  CAS  PubMed  Google Scholar 

  79. Isakova T, Xie H, Messinger S, et al. Inhibitors of mTOR and risks of allograft failure and mortality in kidney transplantation. Am J Transplant. 2013;13(1):100–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Caroti L, Zanazzi M, Paudice N, et al. Conversion from calcineurin inhibitors to everolimus with low-dose cyclosporine in renal transplant recipients with squamous cell carcinoma of the skin. Transplant Proc. 2012;44(7):1926–7.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, Oklahoma University Health Sciences Center, 619 NE 13th Street, Oklahoma City, OK, 73104, USA

    Travis W. Blalock MD & Thomas Stasko MD

  2. Department of Dermatology, Emory University School of Medicine, 1525 Clifton Road, Atlanta, GA, 30306, USA

    Travis W. Blalock MD

Authors
  1. Travis W. Blalock MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas Stasko MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Travis W. Blalock MD .

Editor information

Editors and Affiliations

  1. Brigham & Women's Hosp., Dept of Derm., Mohs & Dermatologic Surgery Center, Jamaica Plain, Massachusetts, USA

    Chrysalyne D. Schmults

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Blalock, T.W., Stasko, T. (2016). Immune Dysfunction and Immunosuppression: Impacts on SCC Incidence, Prognosis, and Management. In: Schmults, C. (eds) High-Risk Cutaneous Squamous Cell Carcinoma. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-47081-7_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-47081-7_10

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-47080-0

  • Online ISBN: 978-3-662-47081-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation